Chemotherapy indications in the treatment of metastases from urological malignancies;Indications de la chimiothérapie dans le traitement des cancers urologiques métastatiques

Progres en Urologie

Volumn 18, Issue SUPPL. 7, 2008, Pages

  Theodore C ^a  

^a FOCH HOSPITAL   (France)

Author keywords

Chemosensitivity; Chemotherapy; Metastasis; Urological tumor; Urology

Indexed keywords

ARTICLE; HUMAN; METASTASIS; PATHOLOGY; URINARY TRACT CANCER;

HUMANS; NEOPLASM METASTASIS; UROLOGIC NEOPLASMS;

EID: 57349146794     PISSN: 11667087     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1166-7087(08)74546-9     Document Type: Article

References (12)

1. Flanigan R.C., Mickisch G., Sylvester R., Tangen C., Van Poppel H., and Crawford ED. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol 171 (2004) 1071-1076
2. Mekhail T.M., Abou-Jawde R.M., Boumerhi G., et al. Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol 23 (2005) 832-841
3. Therasse P., Arbuck S.G., Eisenhauer E.A., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92 (2000) 205-216
4. Gignac G.A., Morris M.J., Heller G., Schwartz L.H., Scher H.I., et al. Assessing outcomes in prostate cancer clinical trials: a twentyfirst century tower of Babel. Cancer 113 (2008) 966-974
5. Mazumdar M., Bajorin D.F., Bacik J., Higgins G., Motzer R.J., and Bosl G.J. Predicting outcome to chemotherapy in patients with germ cell tumors: the value of the rate of decline of human chorionic gonadotrophin and alpha-fetoprotein during therapy. J Clin Oncol 19 9 (2001) 2534-2541
6. 3 CTC version 3: http://ctep.info.nih.gov/reporting/ctc_v30.html.
7. Motzer R.J., Bolger G.B., Boston B., et al. Testicular cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw 4 (2006) 1038-1058
8. Tannock I.F., de Wit R., Berry W.R., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351 (2004) 1502-1512
9. Tannock I.F., Osoba D., Stockler M.R., et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 14 (1996) 1756-1764
10. Sternberg C.N., de Mulder P., Schornagel J.H., et al. Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. Eur J Cancer 42 (2006) 50-54
11. von der Maase H., Sengelov L., Roberts J.T., et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 23 21 (2005) 4602-4608
12. Sternberg C.N., Calabrò F., Pizzocaro G., Marini L., Schnetzer S., and Sella A. Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy. Cancer 92 (2001) 2993-2998